Form 4: HeartSciences Director Bruce Bent Granted 25,000 Stock Options

HeartSciences Inc. Director Bruce Bent was granted 25,000 stock options with an exercise price of $4.37, vesting over time and expiring in 2035.

Summary

• Bruce Bent, a Director of HeartSciences Inc. (HSCS), was granted 25,000 stock options.
• The options have an exercise price of $4.37 per share.
• The grant was effective as of July 9, 2025, following approval by the Issuer's board of directors' compensation committee.
• One-fourth of the options vested on the effective date (July 9, 2025), with the remaining options vesting in equal increments on each successive three-month anniversary of the effective date.
• Vesting is contingent upon Mr. Bent's continued service on the Board through each applicable vesting date.
• The options were granted pursuant to the Issuer's 2023 Equity Incentive Plan, as amended (the "2023 Plan").
• These options are set to expire ten years from the effective date, specifically on July 9, 2035, unless terminated sooner under the 2023 Plan or the underlying grant agreement.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholder value. It is a routine compensation matter and does not indicate operational or financial distress, nor does it represent a significant new strategic development.

Positives

• The grant of stock options to a director helps align management's interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The compensation committee's approval indicates a structured approach to executive and director compensation.

Future Outlook

The options will vest incrementally over time, contingent on the director's continued service, providing a future incentive for performance aligned with the company's stock price.

Management Comments

• The stock options were granted pursuant to the approval of the compensation committee of the Issuer's board of directors.

Industry Context

This transaction represents a standard practice of equity-based compensation for directors in publicly traded companies, aiming to incentivize long-term commitment and align interests with shareholders. It does not reflect broader industry trends or competitive shifts.

Comparison to Industry Standards

• The document does not provide sufficient information regarding the company's overall compensation philosophy or peer group data to conduct a detailed comparison of this specific grant to industry standards or specific comparable companies/projects.

Corporate Governance

Related Party Transactions

• The grant of 25,000 stock options to Bruce Bent, a Director of HeartSciences Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially leading to more shareholder-centric decision-making. However, future exercise of options could lead to minor dilution.

Next Steps

• The remaining three-fourths of the options will vest in equal increments on each successive three-month anniversary of July 9, 2025, subject to continued service.

Key Dates

Keywords

HeartSciences, HSCS, Stock Options, Equity Incentive Plan, Director Compensation, Bruce Bent, SEC Form 4, Insider Transaction